This post was originally published on this site
Moderna (NASDAQ:MRNA) has held discussions with China’s Government regarding supplying its Covid-19 vaccine, according to Reuters on Wednesday.
While they stated no decision has yet been made, Moderna’s CEO Stephane Bancel told Reuters that they are “open” and “have the capacity.”
However, he did not state whether the company has submitted its vaccine for approval in China, which has continued with lockdown restrictions and mass testing. The country has not yet approved any foreign-made Covid vaccines, instead relying on domestically produced shots.
A spokesperson for Moderna reportedly said they have held discussions in the past but could not comment on whether they were still ongoing.
Bancel, speaking in Tokyo, added that Moderna is contemplating building facilities in Japan to make its mRNA products. On Monday, Japan approved vaccine boosters from Moderna and Pfizer (NYSE:PFE).
However, Moderna is suing Pfizer and BioNTech (NASDAQ:BNTX) for patent violation.
